Clinical Trial Update: AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ [Phase 2]

View source ↗

Summary

This report updates a Phase 2 trial of AG-858 in patients with chronic myeloid leukemia who remain cytogenetically positive after treatment with Gleevec, noting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• AG-858
• Gleevec (Imatinib)

Snippet

Sponsor: Agenus Inc. | Conditions: Leukemia, Myeloid, Chronic | Phase 2 | Status: TERMINATED